Activin A marks a novel progenitor cell population during fracture healing and reveals a therapeutic strategy
eLife · 11.12.2023 · 12
DOI: 10.7554/elife.89822 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, online erschienen am 11.12.2023. Verfasst von Lutian Yao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Translational Research Program in Pediatric Orthopaedics, Division of Orthopaedic Surgery, Children's Hospital of Philadelphia, Philadelphia, United …. Hauptthemen laut MEDLINE: Fracture Healing, Bony Callus, Activins. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
Insufficient bone fracture repair represents a major clinical and societal burden and novel strategies are needed to address it. Our data reveal that the transforming growth factor-β superfamily member Activin A became very abundant during mouse and human bone fracture healing but was minimally detectable in intact bones. Single-cell RNA-sequencing revealed that the Activin A-encoding gene Inhba was highly expressed in a unique, highly proliferative progenitor cell (PPC) population with a myofibroblast character that quickly emerged after fracture and represented the center of a developmental trajectory bifurcation producing cartilage and bone cells within callus. Systemic administration of neutralizing Activin A antibody inhibited bone healing. In contrast, a single recombinant Activin A implantation at fracture site in young and aged mice boosted: PPC numbers; phosphorylated SMAD2 signaling levels; and bone repair and mechanical properties in endochondral and intramembranous healing models. Activin A directly stimulated myofibroblastic differentiation, chondrogenesis and osteogenesis in periosteal mesenchymal progenitor culture. Our data identify a distinct population of Activin A-expressing PPCs central to fracture healing and establish Activin A as a potential new therapeutic tool.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Research Program in Pediatric Orthopaedics, Division of Orthopaedic Surgery, Children's Hospital of Philadelphia, Philadelphia, United States.
- Department of Orthopaedics, The First Hospital of China Medical University, Shenyang, China.
- Department of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States.
- Department of Orthopaedic Surgery, Michigan Medicine, University of Michigan, Ann Arbor, United States.
ORCID-Profile: Lutian Yao, Leilei Zhong, Yulong Wei, Joel D Boerckel, Christina Mundy, Ling Qin, Maurizio Pacifici
Förderung
- NIAMS NIH HHS
- NIH HHS
- NIA NIH HHS
- National Institutes of Health
Zitieren
APA
Yao, L., Lu, J., Zhong, L., Wei, Y., Gui, T., Wang, L., Ahn, J., Boerckel, J. D., Rux, D., Mundy, C., Qin, L., & Pacifici, M. (2023). Activin A marks a novel progenitor cell population during fracture healing and reveals a therapeutic strategy. eLife, 12. https://doi.org/10.7554/elife.89822
Vancouver
Yao L, Lu J, Zhong L, Wei Y, Gui T, Wang L, et al. Activin A marks a novel progenitor cell population during fracture healing and reveals a therapeutic strategy. eLife. 2023;12. doi:10.7554/elife.89822
BibTeX
@article{Yao2023,
author = {Yao, Lutian and Lu, Jiawei and Zhong, Leilei and Wei, Yulong and Gui, Tao and Wang, Luqiang and Ahn, Jaimo and Boerckel, Joel D and Rux, Danielle and Mundy, Christina and Qin, Ling and Pacifici, Maurizio},
title = {Activin A marks a novel progenitor cell population during fracture healing and reveals a therapeutic strategy},
journal = {eLife},
year = {2023},
volume = {12},
doi = {10.7554/elife.89822}
}
EUVIMED